1065073-35-9

Basic information

• Product Name: 2-Bromomethyl-oxazole
• Synonyms: 2-Bromomethyl-oxazole
• CAS NO: 1065073-35-9
• Molecular Formula: C₄H₄BrNO
• Molecular Weight: 161.98466
• Mol File: 1065073-35-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 162.2 °C at 760 mmHg
• Flash Point: 51.9 °C
• Appearance: /
• Density: 1.706 g/cm³
• PKA: 0.30±0.10(Predicted)
• CAS DataBase Reference: 2-Bromomethyl-oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromomethyl-oxazole(1065073-35-9)
• EPA Substance Registry System: 2-Bromomethyl-oxazole(1065073-35-9)

Safety Data

• Hazardous Substances Data: 1065073-35-9(Hazardous Substances Data)

Usage

Description

2-Bromomethyl-oxazole is an organic compound characterized by the presence of a bromomethyl group (-CH2Br) attached to the oxazole ring. It is a valuable intermediate in the synthesis of various pharmaceutical compounds due to its unique chemical structure and reactivity.

Uses

Used in Pharmaceutical Industry:
2-Bromomethyl-oxazole is used as a synthetic intermediate for the preparation of substituted oxopyridine derivatives. These derivatives act as inhibitors of factor XIa and plasma kallikrein, which are crucial in the coagulation cascade and inflammation processes. By inhibiting these factors, the substituted oxopyridine derivatives can be useful in treating thrombotic or thromboembolic diseases, such as deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.

Upstream product

• 130551-92-7 (1,3-oxazol-2-yl)methanol 

Relevant articles and documents

SUBSTITUTED OXOPYRIDINE DERIVATIVES

The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

NOVEL ANDROGENS

The compounds of the subject invention have a structure according to formula I: wherein X is S or SO2; R1 is (1C-6C)alkyl, (3C-6C)alkenyl, or (3C-6C)alkynyl, each optionally subst ituted with (3C-6C)cycloalkyl, OH, OC(O)(1C-4C)alkyl, (1C- 4C)alkoxy, halogen, cyano, formyl, C(O)(1C-4C)alkyl, CO2H, CO2(1C- 4C)alkyl, C(O)NR5R6, S(O)(1C-4C)alkyl or S(O)2(1C-4C)alkyl; R2 is hydrogen, (1C-4C)alkyl or C(O)(1C-4C)alkyl; R3 is a phenyl group optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, (1C-4C)fluoroalkoxy, halogen, cyano or nitro; or R3 is a 5- or 6-membered aromatic heterocyclic ring structure optionally substituted with (1C-4C)alkyl, (1C-4C)fluoroalkyl, (1C-4C)alkoxy, halogen or cyano; R4 is a phenyl group or an aromatic 6-membered heterocycle, substituted at the ortho position with 1-hydroxy(1C-4C)alkyl, (1C-4C)alkoxy, C(O)(1C- 4C)alkyl, CO2(1C-4C)alkyl, C(O)NH2, cyano, nitro, or CH=NOR7, and optionally further substituted with (1C-2C)alkyl, (1C-2C)fluoroalkyl or halogen; R5 is 2-pyridyl optionally substituted with (1C-2C)alkyl, (1C- 2C)fluoroalkyl or halogen; or R5 and R6 are independently hydrogen or (1C-4C)alkyl; R7 is hydrogen or C(O)(1C-4C)alkyl; R8 , R9 , R10 are independently hydrogen, (1C-2C)alkyl, fluoro or chloro; or a salt or hydrate form thereof.